Dermatologists and Immunotherapy: Managing Patient Expectations

EP: 1.Prevalence of Cutaneous Squamous Cell Carcinoma (CSCC) & Basal Cell Carcinoma (BCC)

EP: 2.Immunotherapy Landscape in cSCC and BCC

EP: 3.Immunotherapy and Radiation Therapy in cSCC and BCC

EP: 4.Immunotherapy Barriers: Multidisciplinary Approach in cSCC and BCC

EP: 5.Coordination of Care: Interdisciplinary Immunotherapy Challenges in Nonmelanoma Skin Cancers

EP: 6.Multidisciplinary Collaboration: Best Practices for CSCC and BCC Management

Now Viewing

EP: 7.Dermatologists and Immunotherapy: Managing Patient Expectations

EP: 8.Monitoring Immunotherapy Toxicities in CSCC and BCC

EP: 9.Staging Disease and Risk Stratification in CSCC and BCC

EP: 10.Targeted Therapy: Hedgehog Inhibitors in BCC

EP: 11.Socioeconomic Implications of CSCC and BCC

EP: 12.Immunosuppression in CSCC and BCC Treatment

EP: 13.Updates in Therapeutics for Nonmelanoma Skin Cancers

EP: 14.Concluding Thoughts on the Future of CSCC and BCC Care

This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.

Pisano stated dermatologists are very aware of immunotherapy efficacy in advanced cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) from prominent journal coverage. However, solo dermatology practitioners may hesitate to directly administer immunotherapy. She emphasized that dermatologists play key roles in setting patient expectations around neoadjuvant/palliative intent, managing cutaneous adverse effects to enable treatment continuation, and identifying severe reactions necessitating discontinuation. Hamid discussed how immunotherapy toxicities present a “black box” for subspecialists inexperienced with these agents. While serious adverse events are uncommon, serious endocrine, gastrointestinal, and cardiac immune-related adverse events can still occur and may appear long after treatment cessation. He stressed the importance of educating the care team on immune-mediated adverse effects at treatment initiation and through the course of therapy, as unfamiliarity causes heightened anxiety around managing symptoms relative to clinicians well-versed in immunotherapy. Hamid concluded by saying that cross-disciplinary meetings focused on adverse event profiles, timing, and management can build expertise.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.